Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285596> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W4379285596 endingPage "e13067" @default.
- W4379285596 startingPage "e13067" @default.
- W4379285596 abstract "e13067 Background: Ribociclib is, for now, the only CDK4/6 inhibitor having demonstrated a statistically significant increase of overall survival in first-line in hormone receptor-positive, HER2-negative advanced breast cancer. One of the limiting toxicities of ribociclib is the occurrence of grade III/IV hepatobiliary toxicity in approximately 5% of patients. It contraindicates the reintroduction of the drug. Therapeutic options after this type of adverse event are challenging because there are very limited data regarding cross reactivity in risk for hepatic injury between ribociclib, palbociclib or abemaciclib. Methods: We describe a cohort of 28 patients who presented with grade III and/or IV ribociclib-induced hepatitis and who subsequently received another CDK4/6 inhibitor. Cases were collected from the French pharmacovigilance database and additional cases were obtained through institutional databases. Data were retrospectively obtained from patients’ reports. Results: Twenty-eight patients, from 11 centers, presented a grade III (71%, 20 patients) or a grade IV (29%, 8 patients) transaminase elevation with ribociclib. Median transaminase elevation was 12.3 x ULN (upper limit normal) for AST and 15.2 x ULN for ALT. This toxicity occurred within the first 6 months of treatment for all patients except one. Ribociclib was associated with letrozole in 21 patients, fulvestrant in 5 patients and anastrozole or exemestane in 2 patients. No acute liver failure occurred. All patients switched to another CDK4/6 inhibitor (23 patients - 82% - palbociclib and 5 - 18% - abemaciclib) without significant reoccurrence of liver toxicities. Four patients (14%) presented a transient grade 1 or 2 hepatic toxicity (all of them with palbociclib), 20 patients (71%) received the second CDK4/6 inhibitor at full dose. The median follow-up was 16 months. Conclusions: Treatment with palbociclib or abemaciclib after grade III or IV transaminase elevation due to ribociclib is feasible and none of the patients in this cohort exhibited reoccurrence of significant liver toxicity afterwards. Ribociclib liver toxicity occurs mainly during the first 6 months of treatment and takes several months to recover. [Table: see text]" @default.
- W4379285596 created "2023-06-05" @default.
- W4379285596 creator A5007174985 @default.
- W4379285596 creator A5008111826 @default.
- W4379285596 creator A5010185564 @default.
- W4379285596 creator A5025452737 @default.
- W4379285596 creator A5026699354 @default.
- W4379285596 creator A5032365700 @default.
- W4379285596 creator A5034058277 @default.
- W4379285596 creator A5035439475 @default.
- W4379285596 creator A5035492096 @default.
- W4379285596 creator A5040578356 @default.
- W4379285596 creator A5044752757 @default.
- W4379285596 creator A5046459015 @default.
- W4379285596 creator A5050148338 @default.
- W4379285596 creator A5058770898 @default.
- W4379285596 creator A5067835110 @default.
- W4379285596 creator A5075171938 @default.
- W4379285596 creator A5080320132 @default.
- W4379285596 creator A5081504186 @default.
- W4379285596 creator A5083248016 @default.
- W4379285596 creator A5083754996 @default.
- W4379285596 date "2023-06-01" @default.
- W4379285596 modified "2023-09-27" @default.
- W4379285596 title "Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity." @default.
- W4379285596 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e13067" @default.
- W4379285596 hasPublicationYear "2023" @default.
- W4379285596 type Work @default.
- W4379285596 citedByCount "0" @default.
- W4379285596 crossrefType "journal-article" @default.
- W4379285596 hasAuthorship W4379285596A5007174985 @default.
- W4379285596 hasAuthorship W4379285596A5008111826 @default.
- W4379285596 hasAuthorship W4379285596A5010185564 @default.
- W4379285596 hasAuthorship W4379285596A5025452737 @default.
- W4379285596 hasAuthorship W4379285596A5026699354 @default.
- W4379285596 hasAuthorship W4379285596A5032365700 @default.
- W4379285596 hasAuthorship W4379285596A5034058277 @default.
- W4379285596 hasAuthorship W4379285596A5035439475 @default.
- W4379285596 hasAuthorship W4379285596A5035492096 @default.
- W4379285596 hasAuthorship W4379285596A5040578356 @default.
- W4379285596 hasAuthorship W4379285596A5044752757 @default.
- W4379285596 hasAuthorship W4379285596A5046459015 @default.
- W4379285596 hasAuthorship W4379285596A5050148338 @default.
- W4379285596 hasAuthorship W4379285596A5058770898 @default.
- W4379285596 hasAuthorship W4379285596A5067835110 @default.
- W4379285596 hasAuthorship W4379285596A5075171938 @default.
- W4379285596 hasAuthorship W4379285596A5080320132 @default.
- W4379285596 hasAuthorship W4379285596A5081504186 @default.
- W4379285596 hasAuthorship W4379285596A5083248016 @default.
- W4379285596 hasAuthorship W4379285596A5083754996 @default.
- W4379285596 hasConcept C121608353 @default.
- W4379285596 hasConcept C126322002 @default.
- W4379285596 hasConcept C141071460 @default.
- W4379285596 hasConcept C197934379 @default.
- W4379285596 hasConcept C207103383 @default.
- W4379285596 hasConcept C2775930923 @default.
- W4379285596 hasConcept C2777176818 @default.
- W4379285596 hasConcept C2777793932 @default.
- W4379285596 hasConcept C2779744173 @default.
- W4379285596 hasConcept C2780482068 @default.
- W4379285596 hasConcept C29730261 @default.
- W4379285596 hasConcept C44249647 @default.
- W4379285596 hasConcept C530470458 @default.
- W4379285596 hasConcept C71924100 @default.
- W4379285596 hasConcept C90924648 @default.
- W4379285596 hasConceptScore W4379285596C121608353 @default.
- W4379285596 hasConceptScore W4379285596C126322002 @default.
- W4379285596 hasConceptScore W4379285596C141071460 @default.
- W4379285596 hasConceptScore W4379285596C197934379 @default.
- W4379285596 hasConceptScore W4379285596C207103383 @default.
- W4379285596 hasConceptScore W4379285596C2775930923 @default.
- W4379285596 hasConceptScore W4379285596C2777176818 @default.
- W4379285596 hasConceptScore W4379285596C2777793932 @default.
- W4379285596 hasConceptScore W4379285596C2779744173 @default.
- W4379285596 hasConceptScore W4379285596C2780482068 @default.
- W4379285596 hasConceptScore W4379285596C29730261 @default.
- W4379285596 hasConceptScore W4379285596C44249647 @default.
- W4379285596 hasConceptScore W4379285596C530470458 @default.
- W4379285596 hasConceptScore W4379285596C71924100 @default.
- W4379285596 hasConceptScore W4379285596C90924648 @default.
- W4379285596 hasIssue "16_suppl" @default.
- W4379285596 hasLocation W43792855961 @default.
- W4379285596 hasOpenAccess W4379285596 @default.
- W4379285596 hasPrimaryLocation W43792855961 @default.
- W4379285596 hasRelatedWork W2161047589 @default.
- W4379285596 hasRelatedWork W2474699717 @default.
- W4379285596 hasRelatedWork W2610563129 @default.
- W4379285596 hasRelatedWork W2891913333 @default.
- W4379285596 hasRelatedWork W2924345863 @default.
- W4379285596 hasRelatedWork W2944149165 @default.
- W4379285596 hasRelatedWork W3016781567 @default.
- W4379285596 hasRelatedWork W3026185380 @default.
- W4379285596 hasRelatedWork W3096462237 @default.
- W4379285596 hasRelatedWork W4281938012 @default.
- W4379285596 hasVolume "41" @default.
- W4379285596 isParatext "false" @default.
- W4379285596 isRetracted "false" @default.
- W4379285596 workType "article" @default.